Evaluation of the Effectiveness of a Multimodal Complementary Medicine Program for Improving the Quality of Life of Cancer Patients During Adjuvant Radiotherapy And/or Chemotherapy or Outpatient Aftercare
Affiliations
Objectives: Evidence for complementary therapies as important strategies to relieve cancer treatment-associated symptoms is increasing. Mostly, these complementary therapies start at the end of adjuvant treatments, resulting in a long delay until the well-being of patients is addressed. Further, long distances between the rehabilitation center and the patients' residence hinder patients' compliance.
Methods: The multimodal outpatient LOTUS Care Cure Project (LCCP) was tested in a randomized controlled trial including patients of various cancer entities and stages while on adjuvant chemotherapy and/or radiotherapy or outpatient aftercare. The intervention group received the LCCP additionally to the conventional treatment (LCCP group, n = 50). The control group (CG) was split into 2 groups, with (CG1, n = 33) and without (CG2, n = 17) weekly talks. The primary endpoint was quality of life (QoL) after 3 months.
Results: In the LCCP group, QoL significantly improved after 3 months compared to CG2 (p = 0.022) but not compared to CG1. Other parameters showing a significant improvement were cognitive (p < 0.05, vs. CG1 and CG2) and social function (p < 0.05, vs. CG2).
Conclusions: This pilot study describes a multimodal outpatient complementary therapy program conducted in parallel with conventional therapies and its potential to significantly improve QoL and reduce treatment-associated side effects. To substantiate these data, multicenter trials are needed.
Youn B, Kim J, Jo Y, Yoon S, Im J, Kim H Integr Cancer Ther. 2023; 22:15347354231218255.
PMID: 38099482 PMC: 10725141. DOI: 10.1177/15347354231218255.
Mulder L, Busch M, Kristoffersen A, Nordberg J, van der Werf E BMC Complement Med Ther. 2022; 22(1):43.
PMID: 35168630 PMC: 8845358. DOI: 10.1186/s12906-022-03528-x.
Anti-tumor activities of saponins and potential biomarkers in prostate cancer.
He S, Lyu F, Lou L, Liu L, Li S, Jakowitsch J J Ginseng Res. 2021; 45(2):273-286.
PMID: 33841008 PMC: 8020356. DOI: 10.1016/j.jgr.2019.12.007.
Lin W, Zhong M, Zhou Q, Zhang Y, Wang H, Zhao Z Cancer Manag Res. 2019; 11:6663-6680.
PMID: 31413628 PMC: 6661376. DOI: 10.2147/CMAR.S195935.
Serre D, Salleron J, Husson M, Leroux A, Gilson P, Merlin J Oncotarget. 2018; 9(63):32232-32237.
PMID: 30181812 PMC: 6114952. DOI: 10.18632/oncotarget.25957.